A Case of Atopic Dermatitis with Alopecia Universalis in a Patient Treated with Abrocitinib

April 2022 in “ JAAD case reports ”

Jiahui Zhao, Lingling Liu

atopic dermatitis alopecia universalis abrocitinib Janus kinase inhibitor JAK inhibitor cytokines tofacitinib AD AU JAK

TLDR Abrocitinib, a JAK inhibitor, may help treat atopic dermatitis and alopecia universalis together.

A 14-year-old girl with severe atopic dermatitis (AD) and alopecia universalis (AU) experienced significant hair regrowth and improvement in AD symptoms after 52 weeks of daily oral abrocitinib (200 mg), a Janus kinase (JAK) 1 inhibitor. Despite a mild relapse of AD, the patient remained satisfied with the treatment outcome, and no significant side effects were observed. This case suggests that abrocitinib can be an effective therapeutic option for patients with AD and refractory AU.

View this study on jaadcasereports.org →

Discuss this study in the Community →

Cited in this study

2 / 2 results

research Alopecia Areata Is Characterized by Dysregulation in Systemic Type 17 and Type 2 Cytokines, Which May Contribute to Disease-Associated Psychological Morbidity

57 citations , July 2019 in “British journal of dermatology/British journal of dermatology, Supplement”

Alopecia areata involves immune system imbalances that may lead to depression and anxiety.

research Simultaneous Improvement of Alopecia Universalis and Atopic Dermatitis in a Patient Treated with a JAK Inhibitor

16 citations , July 2018 in “JAAD case reports”

A JAK inhibitor improved both severe hair loss and chronic skin disease in one patient.

9 / 9 results

research Alopecia Universalis Treated With Tofacitinib: The Role of JAK/STAT Inhibitors in Hair Regrowth

November 2023 in “Cutis”

Tofacitinib helped a woman with total-body hair loss grow her hair back.

research A Case of Atopic Dermatitis with Alopecia Universalis in a Patient Treated with Abrocitinib

11 citations , April 2022 in “JAAD case reports”

Abrocitinib, a JAK inhibitor, may help treat atopic dermatitis and alopecia universalis together.

research Resistant Alopecia Areata Treated with Tofacitinib

1 citations , January 2022 in “International Journal of Trichology”

Tofacitinib can be effective in treating hair loss caused by alopecia areata.

research Tofacitinib Treatment in Patients With Active COVID-19 Infection

2 citations , September 2021 in “Curēus”

Tofacitinib may be safe for COVID-19 patients with alopecia without worsening symptoms, based on two cases.

research Successful Treatment of Severe Alopecia Areata With Oral or Topical Tofacitinib

4 citations , July 2018 in “PubMed”

Oral and topical tofacitinib can help regrow hair in people with severe alopecia areata.

research Tofacitinib (Selective Janus Kinase Inhibitor 1 and 3): A Promising Therapy for the Treatment of Alopecia Areata: A Case Report of Six Patients

24 citations , January 2018 in “International Journal of Trichology”

Tofacitinib helped regrow hair in patients with alopecia, with few side effects.

research Excellent Response to Tofacitinib Treatment in a Patient with Alopecia Universalis

16 citations , January 2017 in “Acta dermatovenerologica Alpina, Pannonica et Adriatica (Tiskana izd.)”

A patient with complete hair loss regrew all her hair using tofacitinib.

research Alopecia Areata Universalis in a Dog

5 citations , June 2015 in “Veterinary dermatology”

A dog with complete hair loss regrew most hair after treatment, with no relapse after stopping treatment.

research PUVA Treatment of Alopecia Areata Totalis and Universalis: A Retrospective Study

39 citations , April 2003 in “Australasian journal of dermatology”

PUVA treatment led to significant hair regrowth in over half of the patients with alopecia areata totalis and universalis.